.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Julphar
Accenture
US Department of Justice
Chubb
Mallinckrodt
Deloitte
Daiichi Sankyo
Fish and Richardson
Argus Health

Generated: July 25, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Pharmaceutical composition
Abstract: Oral pharmaceutical formulations containing ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity.
Inventor(s): Carter; Barry Howard (Kinston, NC), Campbell; Dwayne A (Durham, NC)
Assignee: SmithKline Beecham (Cork) Limited (Carrigaline, County Cork, IE)
Application Number:11/911,843
Patent Claims: 1. An oral pharmaceutical formulation prepared by a process having the steps: (a) admixing and fluidizing N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)et- hyl]amino}methyl)-2-furyl]-4-quinazolinamine ditosylate monohydrate and at least microcrystalline cellulose in a fluid bed granulator to form a fluidized mixture, wherein the N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)et- hyl]amino}methyl)-2-furyl]-4-quinazolinamine ditosylate monohydrate of the fluidized mixture is present in the range of 45 to 57 percent by weight, and the microcrystalline cellulose of the fluidized mixture is present in the range of 43 to 55 percent by weight; (b) granulating said mixture utilizing an aqueous solution of at least povidone to form active granules, wherein the aqueous solution is a 10 to 25 percent solution of povidone in purified water; (c) blending the active granules with at least sodium starch glycolate and at least magnesium stearate to form a compression blend, wherein the active granules are present in a range of 93 to 96 percent by weight, the sodium starch glycolate is present in a range of 3.5 to 5.5 percent by weight, and the magnesium stearate is present in a range of 0.8 to 1.2 percent by weight; (d) compressing the compression blend into a tablet form; and (e) film coating the tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Novartis
QuintilesIMS
Fish and Richardson
McKinsey
Farmers Insurance
Cantor Fitzgerald
Healthtrust
Teva
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot